decreased from the same period last year. Loss for the first quarter of the year 2019 equals ฿ 7.59 million while loss for the same period last year was ฿ 25.15 million. This is due to the company’s bonus
million in 2019, which rocketed year-on-year by Baht 3 .81 million or 508% due chiefly to a reversal of accrued bonus forgone by an executive into other income of Baht 2.25 million. For the Year Ended
bonus forgone by an executive into other income of Baht 2.25 million. For the Year Ended December 31 2019 2018 Change MB % MB % MB % Cost of sales 157.39 41.87 125.04 39.37 32.35 2.50 Selling expenses
in 2018, the company booked additional accrued bonuses while in the past the company paid compensation to employees only in the form of incentives. Therefore, there were both incentives and accrued
expenses to support job expansion, employee bonus, audit fee, internal audit fee, meeting allowance and other compensation for directors. Theses are expenses related to the preparation for listing on the
expenses to support job expension, employee bonus, audit fee, internal audit fee, meeting allowance and other compensation for directors. Theses are expenses related to the preparation for listing on the
is mainly due to increasing in employee salary expenses to support job expansion, employee bonus, audit fee, internal audit fee, meeting allowance and other compensation for directors. Theses are
sales staffs, advertising media fee for product promotion, distribution fee paid to Zuellig Pharma Ltd. under the Distribution Agreement and compensation for distribution of company’ s products in the
%. Excluding, the recognition of the excess of compensation from returning digital television license of Baht 331.35 million, the Group incurred a net loss for the six-month period end 30 June 2019 of Baht